Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more
Taigen Biopharmaceuticals Holdings Ltd (4157) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.070x
Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) has a cash flow conversion efficiency ratio of -0.070x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-62.73 Million) by net assets (NT$892.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taigen Biopharmaceuticals Holdings Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Taigen Biopharmaceuticals Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taigen Biopharmaceuticals Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Man Industries (India) Limited
NSE:MANINDS
|
-0.032x |
|
Deep Value Driller AS
OL:DVD
|
0.957x |
|
Shanghai Conglin Environmental Protection Technology Co. Ltd. A
SHG:688370
|
N/A |
|
Pendrell Corp
PINK:PCOA
|
0.020x |
|
Randon S.A. Implementos e Participações
SA:RAPT3
|
0.134x |
|
Suzhou Novoprotein Scientific Co. Ltd. A
SHG:688137
|
N/A |
|
Savencia SA
PINK:BNGRF
|
0.038x |
|
LITALICO Inc.
F:9N0
|
N/A |
Annual Cash Flow Conversion Efficiency for Taigen Biopharmaceuticals Holdings Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.08 Billion | NT$-173.09 Million | -0.160x | -962.72% |
| 2023-12-31 | NT$1.12 Billion | NT$20.74 Million | 0.019x | +184.54% |
| 2022-12-31 | NT$970.03 Million | NT$-21.27 Million | -0.022x | -104.37% |
| 2021-12-31 | NT$1.25 Billion | NT$629.07 Million | 0.502x | +191.65% |
| 2020-12-31 | NT$442.18 Million | NT$-242.10 Million | -0.548x | -30.30% |
| 2019-12-31 | NT$815.18 Million | NT$-342.52 Million | -0.420x | -80.21% |
| 2018-12-31 | NT$1.09 Billion | NT$-254.93 Million | -0.233x | -24.43% |
| 2017-12-31 | NT$1.42 Billion | NT$-266.93 Million | -0.187x | +17.16% |
| 2016-12-31 | NT$675.62 Million | NT$-152.83 Million | -0.226x | +83.14% |
| 2015-12-31 | NT$441.60 Million | NT$-592.56 Million | -1.342x | -111.73% |
| 2014-12-31 | NT$852.14 Million | NT$-540.03 Million | -0.634x | +78.74% |
| 2013-12-31 | NT$153.77 Million | NT$-458.46 Million | -2.981x | -686.28% |
| 2012-12-31 | NT$372.80 Million | NT$-141.36 Million | -0.379x | +48.69% |
| 2011-12-31 | NT$513.21 Million | NT$-379.23 Million | -0.739x | -1713.58% |
| 2010-12-31 | NT$-4.29 Billion | NT$-196.43 Million | 0.046x | -- |